BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Haviland D, Shia J, D'Angelica M, Fong Y, DeMatteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009;20:1589-95. [PMID: 19491285 DOI: 10.1093/annonc/mdp029] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
2 Callahan MK, Kemeny NE. Implanted Hepatic Arterial Infusion Pumps. The Cancer Journal 2010;16:142-9. [DOI: 10.1097/ppo.0b013e3181d7ea51] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers (Basel) 2010;2:1441-52. [PMID: 24281167 DOI: 10.3390/cancers2031441] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
4 LaFemina J, Jarnagin WR. Surgical management of proximal bile duct cancers. Langenbecks Arch Surg. 2012;397:869-879. [PMID: 22391776 DOI: 10.1007/s00423-012-0928-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
5 Hayashi T, Ishiwatari H, Yoshida M, Sato T, Miyanishi K, Sato Y, Kobune M, Takimoto R, Sonoda T, Kato J. A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. Int J Clin Oncol 2012;17:491-7. [DOI: 10.1007/s10147-011-0320-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Liang H, Hu C, Lu J, Zhang T, Jiang J, Ding D, Du S, Duan S. Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models. J Int Med Res 2021;49:300060521997586. [PMID: 33682491 DOI: 10.1177/0300060521997586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, Gamblin TC. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111:213-220. [PMID: 25176325 DOI: 10.1002/jso.23781] [Cited by in Crossref: 86] [Cited by in F6Publishing: 114] [Article Influence: 10.8] [Reference Citation Analysis]
8 Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2020;6:60-7. [PMID: 31670750 DOI: 10.1001/jamaoncol.2019.3718] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
9 Thng CH, Koh TS, Collins D, Koh DM. Perfusion imaging in liver MRI. Magn Reson Imaging Clin N Am 2014;22:417-32. [PMID: 25086937 DOI: 10.1016/j.mric.2014.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Miyazaki K, Orton MR, Davidson RL, d’Arcy JA, Lewington V, Koh TS, Thng CH, Leach MO, Collins DJ, Koh DM. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology. 2012;263:139-148. [PMID: 22344403 DOI: 10.1148/radiol.12110770] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
11 Liu ZH, Ma YL, He YP, Zhang P, Zhou YK, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep. 2011;38:1769-1775. [PMID: 20835928 DOI: 10.1007/s11033-010-0291-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
12 Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. Radiology. 2016;281:454-464. [PMID: 27171020 DOI: 10.1148/radiol.2016152659] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
13 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
14 Yankeelov TE, Arlinghaus LR, Li X, Gore JC. The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. Semin Oncol 2011;38:16-25. [PMID: 21362513 DOI: 10.1053/j.seminoncol.2010.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
15 Goh V, Gourtsoyianni S, Koh DM. Functional imaging of the liver. Semin Ultrasound CT MR. 2013;34:54-65. [PMID: 23395318 DOI: 10.1053/j.sult.2012.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study. Acad Radiol. 2015;22:1344-1360. [PMID: 26211553 DOI: 10.1016/j.acra.2015.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
17 Ahn SJ, Park MS, Kim KA, Park JY, Kim I, Kang WJ, Lee SK, Kim MJ. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One. 2013;8:e71571. [PMID: 23940769 DOI: 10.1371/journal.pone.0071571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
18 Xu B, Li M, Yu Y, He J, Hu S, Pan M, Lu S, Liao K, Pan Z, Zhou Y, Zhu J. Effects of harmaline on cell growth of human liver cancer through the p53/p21 and Fas/FasL signaling pathways. Oncol Lett 2018;15:1931-6. [PMID: 29434892 DOI: 10.3892/ol.2017.7495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Cercek A, D’angelica M, Power D, Capanu M, Gewirtz A, Patel D, Allen P, Fong Y, Dematteo RP, Jarnagin WR, Kemeny NE. Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab. Ann Surg Oncol 2014;21:479-86. [DOI: 10.1245/s10434-013-3275-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Medical treatment for cholangiocarcinoma. Liver Int 2019;39:123-42. [DOI: 10.1111/liv.14100] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
21 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 302] [Article Influence: 26.6] [Reference Citation Analysis]
22 Goyal L, Qadan M, Zhu AX. Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. JAMA Oncol 2019;5:938-9. [PMID: 31070694 DOI: 10.1001/jamaoncol.2019.0249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Simo KA, Halpin LE, Mcbrier NM, Hessey JA, Baker E, Ross S, Swan RZ, Iannitti DA, Martinie JB. Multimodality treatment of intrahepatic cholangiocarcinoma: A review: Multimodality Therapy of iCCA. J Surg Oncol 2016;113:62-83. [DOI: 10.1002/jso.24093] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
24 Gollub MJ, Cao K, Gultekin DH, Kuk D, Gonen M, Sohn M, Schwartz LH, Weiser MR, Temple LK, Nash GM, Guillem JG, Wang M, Garcia-aguilar J, Goodman K, Paty PB. Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer. Eur Radiol 2013;23:3336-44. [DOI: 10.1007/s00330-013-2984-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
25 Wang C, Yin FF, Chang Z. An efficient calculation method for pharmacokinetic parameters in brain permeability study using dynamic contrast-enhanced MRI. Magn Reson Med 2016;75:739-49. [PMID: 25820381 DOI: 10.1002/mrm.25659] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol 2017;4:99-109. [PMID: 29367874 DOI: 10.2217/hep-2017-0014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
27 Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014;21:3638-45. [PMID: 24817369 DOI: 10.1245/s10434-014-3766-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Keller S, Chapiro J, Brangsch J, Reimann C, Collettini F, Sack I, Savic LJ, Hamm B, Goldberg SN, Makowski M. Quantitative MRI for Assessment of Treatment Outcomes in a Rabbit VX2 Hepatic Tumor Model. J Magn Reson Imaging 2020;52:668-85. [PMID: 31713973 DOI: 10.1002/jmri.26968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Luna A, Pahwa S, Bonini C, Alcalá-Mata L, Wright KL, Gulani V. Multiparametric MR Imaging in Abdominal Malignancies. Magn Reson Imaging Clin N Am 2016;24:157-86. [PMID: 26613880 DOI: 10.1016/j.mric.2015.08.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
30 Yamada A. Quantitative Evaluation of Liver Function Within MR Imaging. In: El-baz AS, Saba L, Suri J, editors. Abdomen and Thoracic Imaging. Boston: Springer US; 2014. pp. 233-51. [DOI: 10.1007/978-1-4614-8498-1_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Buisman FE, Homs MYV, Grünhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, Borel Rinkes IHM, Bruijnen RCG, Cercek A, D'Angelica MI, van Delden OM, Donswijk ML, van Doorn L, Doornebosch PG, Emmering J, Erdmann JI, IJzerman NS, Grootscholten C, Hagendoorn J, Kemeny NE, Kingham TP, Klompenhouwer EG, Kok NFM, Koolen S, Kuhlmann KFD, Kuiper MC, Lam MGE, Mathijssen RHJ, Moelker A, Oomen-de Hoop E, Punt CJA, Te Riele WW, Roodhart JML, Swijnenburg RJ, Prevoo W, Tanis PJ, Vermaas M, Versleijen MWJ, Veuger FP, Weterman MJ, Verhoef C, Groot Koerkamp B. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. BMC Cancer 2019;19:327. [PMID: 30953467 DOI: 10.1186/s12885-019-5515-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
32 Chen J, Yin HB. Dynamic contrast-enhanced magnetic resonance imaging of the liver: Applications in treatment of hepatic malignancies with vascular targeting agents. Shijie Huaren Xiaohua Zazhi 2014; 22(32): 4928-4933 [DOI: 10.11569/wcjd.v22.i32.4928] [Reference Citation Analysis]
33 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
34 Ghodadra A, Xing M, Zhang D, Kim HS. Yttrium-90 Radioembolization Is Cost Effective in Intrahepatic Cholangiocarcinoma: A SEER Medicare Population Study. J Vasc Interv Radiol 2019;30:293-7. [PMID: 30819468 DOI: 10.1016/j.jvir.2018.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sinn M, Nicolaou A, Gebauer B, Podrabsky P, Seehofer D, Ricke J, Dörken B, Riess H, Hildebrandt B. Hepatic Arterial Infusion with Oxaliplatin and 5-FU/Folinic Acid for Advanced Biliary Tract Cancer: A Phase II Study. Dig Dis Sci 2013;58:2399-405. [DOI: 10.1007/s10620-013-2624-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
36 Pietge H, Sánchez-Velázquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, Nguyen-Kim TDL, Breitenstein S, Knuth A, Petrowsky H, Pestalozzi B, Clavien PA, Samaras P. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. Oncology 2021;99:300-9. [PMID: 33657549 DOI: 10.1159/000512967] [Reference Citation Analysis]
37 Thiels CA, D'Angelica MI. Hepatic artery infusion pumps. J Surg Oncol 2020;122:70-7. [PMID: 32215927 DOI: 10.1002/jso.25913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Wang C, Yin FF, Kirkpatrick JP, Chang Z. Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. Technol Cancer Res Treat 2017;16:446-60. [PMID: 27215931 DOI: 10.1177/1533034616649294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Lee JM, Yoon JH, Joo I, Woo HS. Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. Liver Cancer. 2012;1:22-40. [PMID: 24159569 DOI: 10.1159/000339018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
40 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 209] [Article Influence: 29.5] [Reference Citation Analysis]
41 Peng Y, Yu W, Li E, Kang J, Wang Y, Yang Q, Liu B, Zhang J, Li L, Wu J, Jiang J, Wang Q, Chang J. Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2′-Deoxyuridine for the Treatment of Hepatocellular Carcinoma. J Med Chem 2016;59:3661-70. [DOI: 10.1021/acs.jmedchem.5b01807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
42 Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF, Pawlik TM. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217:736-750.e4. [PMID: 23890842 DOI: 10.1016/j.jamcollsurg.2013.05.021] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 9.2] [Reference Citation Analysis]
43 Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One 2016;11:e0163699. [PMID: 27685844 DOI: 10.1371/journal.pone.0163699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
44 Buettner S, Koerkamp BG, Ejaz A, Buisman FE, Kim Y, Margonis GA, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JN, Pawlik TM. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis. J Surg Oncol. 2017;115:312-318. [PMID: 28105651 DOI: 10.1002/jso.24524] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
45 Zhang W, Chen HJ, Wang ZJ, Huang W, Zhang LJ. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model. Eur Radiol 2017;27:2086-94. [PMID: 27488851 DOI: 10.1007/s00330-016-4505-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
46 Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153-9. [PMID: 21677464 DOI: 10.1159/000324704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
47 Taouli B, Johnson RS, Hajdu CH, Oei MT, Merad M, Yee H, Rusinek H. Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 2013;201:795-800. [PMID: 24059368 DOI: 10.2214/ajr.12.9798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
48 Galbán CJ, Galbán S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A, Ross BD. Applications of molecular imaging. Prog Mol Biol Transl Sci. 2010;95:237-298. [PMID: 21075334 DOI: 10.1016/B978-0-12-385071-3.00009-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
49 Sadot E, Simpson AL, Do RK, Gonen M, Shia J, Allen PJ, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR. Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS One 2015;10:e0132953. [PMID: 26207380 DOI: 10.1371/journal.pone.0132953] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
50 Lin M, Tian MM, Zhang WP, Xu L, Jin P. Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. Onco Targets Ther. 2016;9:7029-7037. [PMID: 27895495 DOI: 10.2147/ott.s112555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
51 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
52 Wang CH, Yin FF, Horton J, Chang Z. Review of treatment assessment using DCE-MRI in breast cancer radiation therapy. World J Methodol 2014; 4(2): 46-58 [PMID: 25332905 DOI: 10.5662/wjm.v4.i2.46] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
53 Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging 2019;10:8. [PMID: 30694398 DOI: 10.1186/s13244-019-0690-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
54 Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D, Nakajima T, Hamaguchi T, Shimada Y, Shirao K. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer. 2012;130:2359-2365. [PMID: 21780098 DOI: 10.1002/ijc.26282] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
55 Sommer CM, Kauczor HU, Pereira PL. Locoregional Therapies of Cholangiocarcinoma. Visc Med 2016;32:414-20. [PMID: 28229076 DOI: 10.1159/000453010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
56 Thibodeau-Antonacci A, Petitclerc L, Gilbert G, Bilodeau L, Olivié D, Cerny M, Castel H, Turcotte S, Huet C, Perreault P, Soulez G, Chagnon M, Kadoury S, Tang A. Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magn Reson Imaging 2019;62:78-86. [PMID: 31247250 DOI: 10.1016/j.mri.2019.06.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
57 Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr 2017;6:105-16. [PMID: 28503558 DOI: 10.21037/hbsn.2017.01.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
58 Zhang Y, Liu H, Xiao W, Zhu L, Wang N, He X, Jiang Z, Guan B. Quantitative dynamic contrast-enhanced magnetic resonance imaging in a VX2 rabbit liver tumour model using different gadolinium-based contrast agents: comparison of DCE-MRI quantitative results between Magnevist and Eovist. BJR Case Rep 2017;3:20160099. [PMID: 30363268 DOI: 10.1259/bjrcr.20160099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
59 Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Klimstra DS. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21:2675-2683. [PMID: 24664624 DOI: 10.1245/s10434-014-3649-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
60 Ocuin LM, Tsung A. Robotic liver resection for malignancy: Current status, oncologic outcomes, comparison to laparoscopy, and future applications. J Surg Oncol. 2015;112:295-301. [PMID: 26119652 DOI: 10.1002/jso.23901] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
61 Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol 2015; 7(20): 2292-2302 [PMID: 26380653 DOI: 10.4254/wjh.v7.i20.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
62 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
63 Leal JN, Kingham TP. Hepatic artery infusion chemotherapy for liver malignancy. Surg Oncol Clin N Am. 2015;24:121-148. [PMID: 25444472 DOI: 10.1016/j.soc.2014.09.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
64 Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013;6:51. [PMID: 23842041 DOI: 10.1186/1756-8722-6-51] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
65 Fowler K, Saad NE, Brunt E, Doyle MB, Amin M, Vachharajani N, Tan B, Chapman WC. Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. Ann Surg Oncol 2015;22:4130-7. [PMID: 26293835 DOI: 10.1245/s10434-015-4774-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
66 Massani M, Stecca T, Pauletti B, Marte G, Ruffolo C, Bonariol L, Bassi N. Intrahepatic Cholangiocarcinoma. In: Abdeldayem H, editor. Topics in the Surgery of the Biliary Tree. InTech; 2018. [DOI: 10.5772/intechopen.75516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, Allen PJ, Farges O, Kingham TP, Regimbeau JM, D'Angelica MI, Azoulay D, Jarnagin WR. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg 2016;223:493-505.e2. [PMID: 27296525 DOI: 10.1016/j.jamcollsurg.2016.05.019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
68 Mondaca S, Yarmohammadi H, Kemeny NE. Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:717-29. [PMID: 31472915 DOI: 10.1016/j.soc.2019.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Rossi AJ, Khan TM, Luna AJ, Cercek A, Jarnagin WR, Hernandez JM. Hepatic Artery Infusion Pump (HAIP) Therapy Versus Chemotherapy in the First-Line Setting for Patients with Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2021. [PMID: 34117578 DOI: 10.1245/s10434-021-10279-5] [Reference Citation Analysis]
70 Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018;12:671-681. [PMID: 29911912 DOI: 10.1080/17474124.2018.1489229] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
71 Sommer WH, Sourbron S, Huppertz A, Ingrisch M, Reiser MF, Zech CJ. Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches. Abdom Imaging. 2012;37:164-179. [PMID: 21516381 DOI: 10.1007/s00261-011-9734-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
72 Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol 2011;8:517-27. [PMID: 21522122 DOI: 10.1038/nrclinonc.2011.62] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
73 Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases—current and emerging techniques. Nat Rev Clin Oncol 2010;7:381-93. [DOI: 10.1038/nrclinonc.2010.47] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
74 Jajamovich GH, Huang W, Besa C, Li X, Afzal A, Dyvorne HA, Taouli B. DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience. MAGMA 2016;29:49-58. [PMID: 26646522 DOI: 10.1007/s10334-015-0513-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
75 Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Reference Citation Analysis]
76 Markman M. Cross-trial comparisons in the oncology arena: when is this justified? Oncology 2011;80:151-2. [PMID: 21677463 DOI: 10.1159/000324707] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016;122:758-65. [PMID: 26695839 DOI: 10.1002/cncr.29824] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
78 Chung SR, Choi YJ, Kim HS, Park JE, Shim WH, Kim SJ. Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study. Medicine (Baltimore) 2016;95:e2624. [PMID: 26871782 DOI: 10.1097/MD.0000000000002624] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Idrees K, Bartlett DL. Robotic Liver Surgery. Surgical Clinics of North America 2010;90:761-74. [DOI: 10.1016/j.suc.2010.04.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
80 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Tse AN, Wu N, Patel D, Haviland D, Kemeny N. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 2009;64:935-44. [DOI: 10.1007/s00280-009-0945-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
82 Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, Kuk D, Weiser M, Saltz L, Schrag D, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol 2012;22:821-31. [PMID: 22101743 DOI: 10.1007/s00330-011-2321-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 9.4] [Reference Citation Analysis]
83 Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep. 2011;38:3075-3082. [PMID: 20111907 DOI: 10.1007/s11033-010-9975-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
84 Winfield JM, Payne GS, deSouza NM. Functional MRI and CT biomarkers in oncology. Eur J Nucl Med Mol Imaging 2015;42:562-78. [PMID: 25578953 DOI: 10.1007/s00259-014-2979-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
85 Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84. [PMID: 32203698 DOI: 10.1016/S1470-2045(20)30109-1] [Cited by in Crossref: 222] [Cited by in F6Publishing: 121] [Article Influence: 111.0] [Reference Citation Analysis]
86 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817-837. [PMID: 20637950 DOI: 10.1016/j.suc.2010.04.011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
87 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
88 Yuan H, Zheng B, Tu S. Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer. World J Surg Oncol. 2015;13:320. [PMID: 26596801 DOI: 10.1186/s12957-015-0737-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
89 Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gönen M, Bamboat Z, Shia J, Haviland D, D’Angelica MI, Fong Y. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol. 2011;18:2192-2199. [PMID: 21286939 DOI: 10.1245/s10434-011-1570-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
90 Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel) 2021;13:3091. [PMID: 34205656 DOI: 10.3390/cancers13123091] [Reference Citation Analysis]
91 Zheng K, Wang X, Cao G, Xu L, Zhu X, Fu L, Fu S, Cheng H, Yang R. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer. Cardiovasc Intervent Radiol 2021;44:271-80. [PMID: 33078235 DOI: 10.1007/s00270-020-02661-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Chen BB, Shih TTF. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol 2014; 20(12): 3125-3134 [PMID: 24695624 DOI: 10.3748/wjg.v20.i12.3125] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
93 Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, Pinto A, Franceschelli G, Carrafiello G, Cornalba G, Sofocleous CT. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol 2017;34:11. [PMID: 28008570 DOI: 10.1007/s12032-016-0866-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
94 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
95 Cai Z, He C, Zhao C, Lin X. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol 2021;11:611118. [PMID: 33868997 DOI: 10.3389/fonc.2021.611118] [Reference Citation Analysis]
96 Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017;27:3069-79. [PMID: 27957638 DOI: 10.1007/s00330-016-4670-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
97 De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, Geboes K, Peeters M. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106:1926-33. [PMID: 22596235 DOI: 10.1038/bjc.2012.184] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.8] [Reference Citation Analysis]
98 Massani M, Nistri C, Ruffolo C, Bonariol R, Pauletti B, Bonariol L, Caratozzolo E, Morana G, Bassi N. Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. Updates Surg. 2015;67:389-400. [PMID: 26468142 DOI: 10.1007/s13304-015-0330-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
99 Squires MH, Woelfel I, Cloyd JM, Pawlik TM. Emerging treatment options for cholangiocarcinoma. Expert Opinion on Orphan Drugs 2018;6:527-36. [DOI: 10.1080/21678707.2018.1476235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Reference Citation Analysis]
101 Lewis HL, Bloomston M. Hepatic Artery Infusional Chemotherapy. Surg Clin North Am. 2016;96:341-355. [PMID: 27017868 DOI: 10.1016/j.suc.2015.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
102 Yang JF, Zhao ZH, Zhang Y, Zhao L, Yang LM, Zhang MM, Wang BY, Wang T, Lu BC. Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma. World J Gastroenterol 2016; 22(13): 3652-3662 [PMID: 27053857 DOI: 10.3748/wjg.v22.i13.3652] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
103 Cheng X, Chen C, Xia H, Zhang L, Xu M. 3.0 T Magnetic Resonance Functional Imaging Quantitative Parameters for Differential Diagnosis of Benign and Malignant Lesions of the Breast. Cancer Biother Radiopharm 2021;36:448-55. [PMID: 32716710 DOI: 10.1089/cbr.2019.3040] [Reference Citation Analysis]
104 Lewis H, Ghasabeh M, Khoshpouri P, Kamel I, Pawlik T. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology 2017;26:411-22. [DOI: 10.1016/j.suronc.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
105 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Connell LC, Kemeny NE. Intraarterial Chemotherapy for Liver Metastases. Surg Oncol Clin N Am 2021;30:143-58. [PMID: 33220802 DOI: 10.1016/j.soc.2020.08.005] [Reference Citation Analysis]
107 Kim KA, Park MS, Ji HJ, Park JY, Han KH, Kim MJ, Kim KW. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging. 2014;39:286-292. [PMID: 24302545 DOI: 10.1002/jmri.24161] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
108 Berks M, Little RA, Watson Y, Cheung S, Datta A, O'Connor JPB, Scaramuzza D, Parker GJM. A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: Application to healthy liver, diseased tissue, and hepatocellular carcinoma. Magn Reson Med 2021;86:1829-44. [PMID: 33973674 DOI: 10.1002/mrm.28798] [Reference Citation Analysis]